Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
June 14, 2022 07:00 ET
|
Sio Gene Therapies
NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth...
Sio Gene Therapies Provides Corporate Update
April 27, 2022 16:25 ET
|
Sio Gene Therapies
-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB Securities to advise it on a range of strategic...
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results
February 11, 2022 07:00 ET
|
Sio Gene Therapies
Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9...
Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022
February 02, 2022 07:00 ET
|
Sio Gene Therapies
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the...
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition
January 31, 2022 16:01 ET
|
Sio Gene Therapies
– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease,...
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
November 12, 2021 07:00 ET
|
Sio Gene Therapies
– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF – ...
Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease
November 11, 2021 07:00 ET
|
Sio Gene Therapies
- Completed three successful GMP campaigns using suspension-based manufacturing process- All batches achieved target titers and have successfully completed fill and finish- Qualified Person (QP)...
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
November 01, 2021 07:00 ET
|
Sio Gene Therapies
- Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations- Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff...
Sio Gene Therapies Announces Reorganization of R&D Group
October 21, 2021 17:00 ET
|
Sio Gene Therapies
NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of...
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis
October 21, 2021 08:00 ET
|
Sio Gene Therapies
NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of...